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A B S T R A C T
Background: Many patients present with refractory Status epilepticus (SE) despite multiple anti-epileptic
drugs (AEDs). Lacosamide (LCM) was recently approved as an adjunct AED for partial-onset seizures. It
has unique mechanism of modulating voltage-gated sodium channels by enhancing their slow
inactivation. LCM has demonstrated efﬁcacy in animal models of pharmacoresistant seizures. To date,
there are isolated anecdotal reports of LCM use in SE.
Objective: To report a single center experience with IV Lacosamide in patients with NCSE.
Methods: Pharmacy records were reviewed to identify patients with SE who received IV LCM in our
institution. Data on demographics, response to therapy and adverse effects/outcomes were analyzed. All
patients had continuous EEG monitoring.
Results: 10 patients (4 men, 6 women), age 16–90 years with refractory SE were given LCM. Eight patients
were in focal non-convulsive SE (NCSE), 2 were in generalized non-convulsive SE. The etiologies included
anoxic brain injury, idiopathic, encephalitis, tumor, posterior reversible encephalopathy syndrome
(PRES), stroke, and AVM. IV LCM was added after traditional AEDs, including drug-induced coma in some,
failed to control the SE. NCSE resolved in 7/10 patients whereas 1/10 patient showed partial response
with cessation of NCSE but still frequent electrographic seizures and 2/10 patients were resistant to
therapy.
Conclusions: LCM is a useful adjunct in refractory NCSE. The IV formulation allows prompt administration
in the intensive care unit setting. Response was seen especially in focal SE. Similar to other AEDs, response
was poor in patients with postanoxic injury. Our data is limited by the small number of patients. Larger
controlled studies are necessary to assess accurately the efﬁcacy of IV LCM as an early treatment of SE.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is associated with signiﬁcant morbidity
and mortality. SE is encountered frequently in critical care setting
and is often refractory to treatment. The established paradigm in
most centers for SE treatment utilizes ﬁrst generation AEDs.1–3
Nonconvulsive status epilepticus (NCSE) is a commonly under-
recognized condition in critically ill patients.4 In neurological ICU,
the prevalence of NCSE may be as high as 10.5%.5 The prevalence of
non-convulsive seizures (not NCSE) may be even higher, reaching
18% on continuous EEG monitoring.6 Up to 20% of patients with SE
after initial treatment can evolve to become NCSE.7* Corresponding author at: 8730 Alden Dr #E-204, Los Angeles, CA 90048, United
States. Tel.: +1 310 423 6472; fax: +1 310 423 0148.
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(J.M. Chung), Evgeny.Tsimerinov@cshs.org (E.I. Tsimerinov),
Dawn.Eliashiv@cshs.org (D.S. Eliashiv).
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doi:10.1016/j.seizure.2011.12.008Lacosamide (LCM) is a novel anticonvulsant approved in 2008
by the Food and Drug Administration as an adjunctive therapy for
partial onset seizures in patients with epilepsy aged 17 and older
(United States).8,9 LCM modulates voltage-gated sodium channels
by enhancing slow inactivation without affecting the fast
inactivation,10,11 which is expected to normalize activation
thresholds, thus decreasing pathophysiological neuronal hyper-
excitability. LCM has minimal (<15%) protein binding and drug–
drug interactions.13 Intravenous (IV) formulation is easy to handle,
has the same safety proﬁle as oral formulation.10 The maximum
drug concentration is reached at the end of infusion. To
characterize the effectiveness and role of LCM in SE, mainly in
ICU settings, we retrospectively analyzed the outcome of patients
in SE treated with IV LCM in addition to traditional AEDs.
2. Methods
Consecutive patients who were diagnosed with NCSE at Cedars
Sinai Medical Center, Los Angeles, California between August 2009vier Ltd. All rights reserved.
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accepted deﬁnitions of NCSE. There are no pathognomonic clinical
signs or EEG features that are speciﬁc for NCSE. NCSE can be
deﬁned as a prolonged state of impaired consciousness or altered
sensorium associated with continuous paroxysmal activity or
electrographic discharges on the EEG.4 Pharmacy records were
examined to identify patients who received IV LCM during the
course of their treatment. All patients with the diagnosis of NCSE
were monitored with continuous EEG monitoring. Data including
demographics, etiology, seizure semiology, concomitant AEDs and
outcome was collected utilizing our IRB approved data collection
tool.
3. Results
We identiﬁed 10 patients (4 men and 6 women), ages between
16 and 90 years, with nonconvulsive status epilepticus, treated
with IV Lacosamide. Eight patients had initial clinical presentation
with manual automatisms, focal motor twitching and impaired
consciousness or generalized tonic–clonic activity followed by
persistent focal subclinical, electrographic seizures despite ag-
gressive management, and two patients were in generalized
electrographic status. The etiologies included anoxic brain injury
due to asystole, herpes simplex virus (HSV) encephalitis, idiopath-
ic, glioma, brain metastases, posterior reversible encephalopathy
syndrome (PRES), arteriovenous malformation (AVM) and stroke
(Table 1). SE was the initial presentation in 6/10 patients. Only four
patients had previous history of complex partial seizures second-
ary to a structural lesion.
IV LCM was administered to the patients after standard
treatment for SE failed to control the seizures within the 1st or
2nd day of adequate therapy. The median loading dose of IV LCM
was 200–300 mg infused within 30 min per pharmacy protocol.
Current approved IV loading dose of LCM is up to 200 mg; however
300 mg doses have been used safely as well. The maintenance
dosage ranged from 100 to 200 mg every 12 h. Concomitant AEDs
used prior to the addition of LCM included phenytoin (PHT),
levetiracetam (LEV), valproic acid (VPA), midazolam, propofol and
pentobarbital induced coma. In addition, some of these patients
were given topiramate (TPM) and lamotrigine (LTG) via NG tube.
All the patients received IV lorazepam upon initial presentation.
LCM was the last anti-convulsant added to the regimen preceding
termination of NCSE, only patient #1 had TPM added a few hours
apart from LCM. Serum levels of all AEDs were maintained
therapeutic. The AEDs were added in sequence of treating
physicians’ preference. The ﬁrst line therapy was according to
current guidelines. The maintenance dose of PHT ranged from 300
to 400 mg/day, LEV 3000–4000/day, TPM 300–400/day, clonaze-
pam 2–4 mg/day, phenobarbital 120–180 mg/day. The continuous
anaesthetics were titrated to the desired level of anaesthesia and
EEG response based on hemodynamic and side effect tolerability.
SE resolved in 7/10 patients. Although only one patient (patient
#3, Table 1) demonstrated an immediate termination of SE after
the LCM administration, the other patients eventually had
resolution of SE. We do not have more precise timing between
adding the LCM and termination of NCSE in all patients due to
retrospective nature of this study. All seven patients eventually
recovered close to their pre-admission baseline state with a seizure
free outcome (follow-up range 1 week–10 months). Oral LCM as an
adjunct AED was maintained in most of these patients (Table 1).
Patient #9 (Table 1) had advanced lung cancer with widespread
brain metastases, resulting in cerebral edema. She continued to
have periodic lateralized epileptiform discharges (PLEDs) on EEG,
but less persistent, and fewer brief electrographic seizures,
and was eventually given comfort care per the family’s wishes.
Two patients with post-anoxic brain injury and refractorynon-convulsive generalized SE did not respond to treatment, and
they had their care withdrawn. Patient #10 (Table 1) had advanced
breast cancer without brain metastases showed complete resolution
of electrographic seizures and PLEDs on EEG and remarkable
improvement of neurological status; however, she later suffered
multiple non-neurological complications and was given comfort
care as well. No patient in our study population had a documented
early or delayed adverse side effect including a hemodynamic
instability during the infusion, injection site reactions, rash, change
in other AED serum levels or electrolytes in a close relationship to
LCM introduction or signiﬁcant drug–drug interactions. On post
discharge follow up ranging 3 weeks to 10 month depending on
discharge date in relation to the study period, none of the patients
had records of readmission for seizures and some remained seizure
free on and off AEDs on follow up clinic visit.
4. Discussion
We reviewed our initial clinical experience with intravenous
LCM in patients with focal partial and generalized NCSE in our
medical center with a large neurological intensive care unit (ICU)
and about 400 continuous EEG monitoring studies per year. To date
there are no universally accepted deﬁnitions of NCSE.4 There are no
pathognomonic clinical signs or EEG features that are speciﬁc for
NCSE. NCSE can be deﬁned as a prolonged state of impaired
consciousness or altered sensorium associated with continuous
paroxysmal activity or electrographic discharges on the EEG.4 Our
deﬁnition of NCSE was similar, continuous evolving electrographic
rhythmic patterns in patients without obvious clinical behavior
such as motor twitching, jerking, head and gaze deviation,
automatisms, but with persistent confusional state, obtundation
and coma without return to baseline level of mentation and
interaction. The patients with periodic non-sustained and non-
evolving EEG patterns were not included. Some of the initial
behavior included manual automatisms and limb stiffening
(Patient #1), focal facial and arm twitching (patients #3, 5 and
7) with impaired consciousness, generalized tonic–clonic activity
(patients #4 and 10) without recovery to baseline state followed by
subclinical persistent electrographic activity without improve-
ment of cognition. Lacosamide is not FDA approved for treatment
of status epilepticus; however multiple randomized pre-clinical
and clinical studies have shown LCM as an effective adjunct anti-
epileptic medication.9,16–18 However, there is limited data con-
sisting of mostly single case reports on the efﬁcacy of LCM in
controlling SE. Tilz et al. reported cessation of convulsive SE with a
single dose of LCM after lorazepam, levetiracetam (LVT) and
midazolam failed to control the seizures.14 Turpı´n-Fenoll et al.
reported a 72-year-old male with an ischemic lesion and partial SE
successfully treated with LCM,12 and another patient with post
anoxic, late-onset myoclonus that responded well to LCM.15
Lacosamide has shown effectiveness in a number of animal
models, such as maximal electroshock (MES) test induced seizures
in rats and mice by preventing the seizure spread. In a
pentylenetetrazol paradigm, LCM was shown to lack a pro-
convulsant or seizure-threshold lowering activity. Interestingly,
LCM displayed a higher potency in the 6-Hz model of psychomotor
seizures—a model for treatment resistant seizures19 compared to
that of newer generation AEDs, thus suggesting a potential role in
pharmacoresistant seizures.20 In the homocysteine model of self-
sustaining status epilepticus (SSSE), LCM appeared less potent
against generalized tonic clonic seizures (GTCS); however, its
efﬁcacy was potentiated by low dose diazepam.19 Furthermore,
LCM reduces the cumulative SSSE duration and neuronal
hippocampal damage following perforant path stimulation, and
prevents spontaneous GTCS in the cobalt/homocysteine model of
SSSE based on previous works.21 In fact, there are preliminary
Table 1
Patient characteristics, EEG ﬁndings, concomitant AEDs, outcome.
Patient Age/sex Diagnosis EEG localization
of ictal patterns
Other AEDs Outcome Previous
seizures
Discharge AEDs
1 70 M Unknown Left temporo-occipital region PHT, LEV, MDZ, PB, TPM,
PTB Clonazepam
Recovered
No seizures
None LCM
LEV
TPM
2 90 F Asystole Persistent generalized
spike wave complexes
LEV, VPA, Propofol, MDZ Withdrawal of care None
3 33 M Glioma
Resection
Left fronto-temporal PHT, LEV Recovered
No seizures
Yes LCM
LEV
4 81 F HSV encephalitis Left hemispheric PHT, LEV Recovered
No seizures
None PHT, LCM, LEV
5 16 F Frontal AVM
Resection
Anterior quadrant LEV (allergy to other AEDs) Recovered
No seizures
Yes LCM
LEV
6 61 M Asystole GPED PHT, LEV Withdrawal of care None
7 61 M Multifocal glioma Left hemispheric seizures
and frontotemporal PLED
LEV
PHT
VPA
Recovered/some
seizures
Yes LCM
LEV
8 46 F Left hemispheric
chronic infarct
Left posterior quadrant PHT
LEV
VPA
Recovered Yes VPA
LEV
LCM
9 60 F Multifocal brain metastases Left posterior quadrant PHT
MDZ
PTB
Comfort care/EEG:
PLEDs, fewer seizures
None
10 55 F PRES/advanced
breast CA without
brain metastasis
Occipital region PHT
MDZ
LEV
Resolution of seizures.
Later, comfort care
None
Abbreviations: AED: antiepileptic drugs; AVM: arteriovenous malformation; GPED: generalized periodic epileptiform discharges; HSV: herpes simplex virus; LCM:
Lacosamide; LEV: levetiracetam; PHT: phenytoin; PTB: pentobarbital; PRES: posterior reversible encephalopathy syndrome; TPM: topiramate; MDZ: midazolam; VPA:
valproic acid.
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SE when other agents are felt to be unsuitable.25,26
All, but one of our patients with focal partial NCSE (7/8), showed
resolution of the ictal electrographic discharges. Subsequently, six
patients improved and remained seizure free upon discharge. 6/6
patients were discharged on a combination of LCM and LEV. In
addition PHT was the third AED on discharge in 2 patients, TPM in
one and VPA in one (Table 1). One patient (1/8) with multiple brain
metastases did show a partial response as her EEG demonstrated
persistent PLEDs but fewer and shorter electrographic seizures.
Two other patients who suffered cardiopulmonary arrest and
resultant anoxic brain injury showed no response to multiple
anticonvulsant therapy including Lacosamide and remained in
generalized NCSE. However, it should be noted these patients also
had signiﬁcant co-morbidities due to multiorgan failure. Our
retrospective review was also notable for 9/10 subjects already
receiving levetiracetam prior to adding the Lacosamide yet still
requiring additional AEDs, which questions the efﬁcacy of
levetiracetam in acute settings as well.
In summary, our study data suggests that IV LCM can be
efﬁcacious and safe in managing patients with refractory NCSE as
an adjunctive agent. Although refractory SE is known to be more
resistant to treatment,23,24 7/10 patients in our study demonstrat-
ed a response with the cessation of SE after the addition of LCM.
There was, however, no demonstrated efﬁcacy in treating
generalized NCSE associated with post-anoxic injury, which is
known to be highly resistant to anti-epileptic medications22,27 and
may represent separate subset. No adverse side effects or drug–
drug interactions were seen in these acutely ill patients. The
availability of IV formulation provides the beneﬁt of easier
administration and rapid action when oral intake is contra-
indicated. LCM is renally excreted; and the dosage should be
adjusted in patients with renal failure. We cannot comment as to
the efﬁcacy of LCM as initial treatment of SE since all our patients
had LCM administered as adjunct therapy. There is currently no
evidence supporting the use of LCM as an initial agent for SE. We
can not exclude a possibility of selection bias affecting our results
given the study period of one year and our tertiary care centerhaving a high number of neurosurgical patients with acute CNS
insults that might not represent the typical population presenting
with status epilepticus. In other centers, cerebrovascular disease
may account for a higher percentage of status epilepticus with a
potentially differing response. Our results are limited due to the
small sample size, the lack of randomization and inability to
standardize concomitant AEDs. Larger, prospective trials are
needed to evaluate the efﬁcacy of IV LCM as an early use adjunct
or initial treatment in patients with refractory SE.
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